Welcome to our dedicated page for Portage Biotech news (Ticker: PRTG), a resource for investors and traders seeking the latest updates and insights on Portage Biotech stock.
The PRTG news page on Stock Titan provides an archive of disclosures and press releases for Portage Biotech Inc., now renamed AlphaTON Capital Corp. Company communications describe a transition from being solely a clinical-stage immuno-oncology company to operating with two primary business lines: a legacy oncology research and development portfolio and a new digital asset treasury strategy centered on The Open Network (TON) token and the Telegram ecosystem.
News items associated with the former PRTG symbol include updates on clinical and preclinical programs such as PORT-6, a highly selective A2A adenosine receptor antagonist, and PORT-7, a selective A2B adenosine receptor inhibitor. Press releases report confirmatory and promising preclinical data in mesothelioma models, plans to commence first-in-human trials for PORT-7, and the resumption of enrollment in the final dose-escalation cohort for PORT-6 in the ADPORT-601 Phase 1b trial. Additional oncology-related news covers the re-launch of the adenosine-focused subsidiary as Cyncado Therapeutics and strategic transactions such as a stock-for-stock exchange with Compedica Holdings Limited.
Filings and press releases also describe capital markets developments, including private financings, at-the-market offering agreements, and Nasdaq listing compliance updates. More recent news under the company’s new name, AlphaTON Capital Corp, focuses on the launch of a TON digital asset treasury strategy, a significant private placement involving both cash and cryptocurrency, and loan and treasury management agreements intended to support large-scale TON acquisitions and management.
Investors and researchers can use this page to review how the business mix, financing activities, and strategic direction have evolved from Portage Biotech’s immuno-oncology focus under PRTG to AlphaTON Capital Corp’s combined digital asset and legacy oncology strategy associated with the ATON ticker.
Portage Biotech Inc. (NASDAQ: PRTG) announces participation in investor conferences in September 2021, enhancing investor outreach. Management will present at three notable events: the H.C. Wainwright 23rd Annual Global Investor Conference on September 13, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, and the 2021 Cantor Virtual Global Healthcare Conference on September 29. Recordings of the Oppenheimer and Cantor presentations will be archived on Portage's website. The company focuses on immuno-oncology therapies targeting cancer treatment resistance.
Portage Biotech (NASDAQ: PRTG) reported raising $29 million to expedite its clinical pipeline focused on cancer treatment innovation. The funding enables advancement of Phase 1 and Phase 2 trials for lead iNKT agonists PORT-2 and PORT-3. Despite a net loss of $3.2 million for the quarter ending June 30, 2021, up from $0.7 million the prior year, the company’s cash balance was approximately $28.6 million. The company plans to present its advancements at several upcoming conferences, further enhancing its visibility in the immuno-oncology sector.
Portage Biotech Inc. (NASDAQ: PRTG) provided a corporate update reflecting significant advancements in its immuno-oncology pipeline. The company has successfully transitioned three assets into clinical trials, raising over $29 million since March 31, 2021, including a $26.5 million public offering. Portage aims to leverage novel iNKT agonists for treating cancer, with two lead assets, PORT-2 and PORT-3, currently in clinical trials. The company anticipates multiple data readouts in the upcoming 12-24 months, supported by enhanced investor relations and strategic partnerships.
Portage Biotech Inc. (NASDAQ: PRTG) has initiated the first patient dosing in the Oxford-led IMP-MEL study, a clinical trial assessing the safety and efficacy of PORT-2, an iNKT agonist for treating solid tumors. Preclinical results indicate PORT-2 promotes strong immune responses and may enhance the effectiveness of PD-1 inhibitors like Keytruda. The study will enroll 100 patients and aims to evaluate PORT-2 both alone and in combination with checkpoint therapies. Positive preclinical data positions PORT-2 as a potential solution for checkpoint-resistant tumors, bolstering its clinical importance.
Portage Biotech (NASDAQ: PRTG) reported a transformative year in its press release dated July 28, 2021, detailing significant corporate and clinical milestones for the fiscal year ended March 31, 2021. The company raised over $29 million, ensuring a two-year cash runway for ongoing clinical trials. Despite a net loss of $17.2 million, an increase from $7.2 million the previous year, Portage is advancing its lead iNKT agonists and presented positive interim data from clinical trials. With a focus on immuno-oncology, the company has divested legacy businesses to concentrate on high-potential assets.